|
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SOX4 |
Gene summary for SOX4 |
| Gene information | Species | Human | Gene symbol | SOX4 | Gene ID | 6659 |
| Gene name | SRY-box transcription factor 4 | |
| Gene Alias | CSS10 | |
| Cytomap | 6p22.3 | |
| Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | Q06945 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6659 | SOX4 | GSM4909280 | Human | Breast | Precancer | 3.15e-02 | 2.05e-01 | 0.0305 |
| 6659 | SOX4 | GSM4909281 | Human | Breast | IDC | 1.62e-19 | 4.90e-01 | 0.21 |
| 6659 | SOX4 | GSM4909282 | Human | Breast | IDC | 5.35e-05 | 3.25e-01 | -0.0288 |
| 6659 | SOX4 | GSM4909285 | Human | Breast | IDC | 1.84e-09 | 3.15e-01 | 0.21 |
| 6659 | SOX4 | GSM4909286 | Human | Breast | IDC | 4.56e-33 | 5.72e-01 | 0.1081 |
| 6659 | SOX4 | GSM4909293 | Human | Breast | IDC | 3.76e-03 | 1.30e-01 | 0.1581 |
| 6659 | SOX4 | GSM4909294 | Human | Breast | IDC | 4.88e-06 | -4.46e-01 | 0.2022 |
| 6659 | SOX4 | GSM4909296 | Human | Breast | IDC | 8.39e-03 | 7.04e-02 | 0.1524 |
| 6659 | SOX4 | GSM4909297 | Human | Breast | IDC | 1.63e-10 | -4.43e-02 | 0.1517 |
| 6659 | SOX4 | GSM4909302 | Human | Breast | IDC | 1.25e-13 | -5.79e-01 | 0.1545 |
| 6659 | SOX4 | GSM4909304 | Human | Breast | IDC | 9.88e-04 | -2.44e-01 | 0.1636 |
| 6659 | SOX4 | GSM4909311 | Human | Breast | IDC | 3.84e-33 | -3.33e-01 | 0.1534 |
| 6659 | SOX4 | GSM4909313 | Human | Breast | IDC | 2.12e-05 | 2.96e-01 | 0.0391 |
| 6659 | SOX4 | GSM4909315 | Human | Breast | IDC | 2.72e-12 | 1.93e-01 | 0.21 |
| 6659 | SOX4 | GSM4909316 | Human | Breast | IDC | 5.26e-04 | -3.50e-01 | 0.21 |
| 6659 | SOX4 | GSM4909317 | Human | Breast | IDC | 4.98e-07 | 3.98e-01 | 0.1355 |
| 6659 | SOX4 | GSM4909319 | Human | Breast | IDC | 1.32e-48 | -8.41e-01 | 0.1563 |
| 6659 | SOX4 | GSM4909320 | Human | Breast | IDC | 3.57e-02 | 1.83e-01 | 0.1575 |
| 6659 | SOX4 | GSM4909321 | Human | Breast | IDC | 5.88e-05 | -4.46e-02 | 0.1559 |
| 6659 | SOX4 | ctrl6 | Human | Breast | Precancer | 3.33e-12 | 5.34e-01 | -0.0061 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD | ![]() |
| Colorectum | SER | ![]() |
| Colorectum | MSS | ![]() |
| Colorectum | MSI-H | ![]() |
| Colorectum | FAP | ![]() |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00427691 | Colorectum | MSS | DNA damage response, detection of DNA damage | 7/3467 | 13/18723 | 4.46e-03 | 3.15e-02 | 7 |
| GO:0001655 | Colorectum | MSS | urogenital system development | 81/3467 | 338/18723 | 6.88e-03 | 4.43e-02 | 81 |
| GO:0002244 | Colorectum | MSS | hematopoietic progenitor cell differentiation | 32/3467 | 114/18723 | 8.07e-03 | 4.91e-02 | 32 |
| GO:00064173 | Colorectum | MSI-H | regulation of translation | 73/1319 | 468/18723 | 9.89e-11 | 1.66e-08 | 73 |
| GO:00457273 | Colorectum | MSI-H | positive regulation of translation | 33/1319 | 136/18723 | 2.28e-10 | 3.60e-08 | 33 |
| GO:00342503 | Colorectum | MSI-H | positive regulation of cellular amide metabolic process | 34/1319 | 162/18723 | 7.07e-09 | 8.93e-07 | 34 |
| GO:19033203 | Colorectum | MSI-H | regulation of protein modification by small protein conjugation or removal | 43/1319 | 242/18723 | 1.60e-08 | 1.85e-06 | 43 |
| GO:00313963 | Colorectum | MSI-H | regulation of protein ubiquitination | 39/1319 | 210/18723 | 2.12e-08 | 2.36e-06 | 39 |
| GO:00313973 | Colorectum | MSI-H | negative regulation of protein ubiquitination | 22/1319 | 83/18723 | 4.06e-08 | 4.26e-06 | 22 |
| GO:19033213 | Colorectum | MSI-H | negative regulation of protein modification by small protein conjugation or removal | 23/1319 | 95/18723 | 1.25e-07 | 1.19e-05 | 23 |
| GO:00723313 | Colorectum | MSI-H | signal transduction by p53 class mediator | 29/1319 | 163/18723 | 3.27e-06 | 1.82e-04 | 29 |
| GO:00508213 | Colorectum | MSI-H | protein stabilization | 32/1319 | 191/18723 | 3.95e-06 | 2.13e-04 | 32 |
| GO:00316473 | Colorectum | MSI-H | regulation of protein stability | 43/1319 | 298/18723 | 5.66e-06 | 2.86e-04 | 43 |
| GO:19049513 | Colorectum | MSI-H | positive regulation of establishment of protein localization | 44/1319 | 319/18723 | 1.42e-05 | 6.31e-04 | 44 |
| GO:00512223 | Colorectum | MSI-H | positive regulation of protein transport | 40/1319 | 303/18723 | 9.21e-05 | 2.94e-03 | 40 |
| GO:00427692 | Colorectum | MSI-H | DNA damage response, detection of DNA damage | 6/1319 | 13/18723 | 1.35e-04 | 3.98e-03 | 6 |
| GO:00342843 | Colorectum | MSI-H | response to monosaccharide | 31/1319 | 225/18723 | 2.56e-04 | 6.57e-03 | 31 |
| GO:00097433 | Colorectum | MSI-H | response to carbohydrate | 33/1319 | 253/18723 | 4.53e-04 | 9.61e-03 | 33 |
| GO:00488723 | Colorectum | MSI-H | homeostasis of number of cells | 34/1319 | 272/18723 | 8.10e-04 | 1.49e-02 | 34 |
| GO:00457853 | Colorectum | MSI-H | positive regulation of cell adhesion | 48/1319 | 437/18723 | 1.47e-03 | 2.23e-02 | 48 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SOX4 | SNV | Missense_Mutation | rs777539753 | c.1172N>T | p.Ser391Phe | p.S391F | Q06945 | protein_coding | deleterious(0) | possibly_damaging(0.854) | TCGA-A7-A6VW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| SOX4 | SNV | Missense_Mutation | novel | c.1367A>T | p.Glu456Val | p.E456V | Q06945 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SOX4 | SNV | Missense_Mutation | novel | c.1210N>T | p.Asp404Tyr | p.D404Y | Q06945 | protein_coding | deleterious(0.01) | probably_damaging(0.936) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SOX4 | SNV | Missense_Mutation | novel | c.1390G>C | p.Glu464Gln | p.E464Q | Q06945 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-VS-A9UC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| SOX4 | SNV | Missense_Mutation | c.331G>C | p.Glu111Gln | p.E111Q | Q06945 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SOX4 | SNV | Missense_Mutation | c.299N>G | p.Leu100Arg | p.L100R | Q06945 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SOX4 | SNV | Missense_Mutation | c.237N>T | p.Glu79Asp | p.E79D | Q06945 | protein_coding | tolerated(0.06) | benign(0.444) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SOX4 | SNV | Missense_Mutation | c.237N>T | p.Glu79Asp | p.E79D | Q06945 | protein_coding | tolerated(0.06) | benign(0.444) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SOX4 | SNV | Missense_Mutation | novel | c.1252T>G | p.Ser418Ala | p.S418A | Q06945 | protein_coding | tolerated(0.16) | benign(0.021) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SOX4 | SNV | Missense_Mutation | novel | c.1166N>G | p.Ser389Cys | p.S389C | Q06945 | protein_coding | deleterious(0) | benign(0.009) | TCGA-AX-A3G3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |